For Exhibitors
9. & 10. March 2021
ExciPerience will be a completely new virtual event experience and fully focussed
on all the topics around pharmaceutical excipients
Why you should participate as an exhibitor and sponsor?
Get in touch
Show your products and solutions
Adress a dedicated audience
Your company, your expertise and your products will be presented stepwise to the participants
The communication starts more than two months before the actual event by several teasers (including small videos)
Confirmed Speakers
Jennifer Cain Birkmose is Vice President, Global Head of Patient Access and Community Engagement of sobi – Swedish Orphan Biovitrum AB (publ). Moreover, she is Member of the Board of Directors at Medicines for Malaria Venture.
Her professional experience and personal motivations are driven by an interest in advancing the health of populations globally. She sees the advancement of public health and improving the quality, efficiency and effectiveness of health care systems as intertwined.
Ana Gutierrez has a pharmaceutical engineering degree from the National Polytechnic Institute and a Masters in Pharmaceutical Sciences from the Metropolitan Autonomous University. She gained considerable industrial experience through positions as manufacturing technology scientist at Bristol Myers Squibb in Mexico, where she also held an Assistant Professor position at the Pharmacy School at the Metropolitan Autonomous University.
At Gattefossé Ana is responsible for providing formulation and process development technical support and delivering internal and external training programs for customers and European universities.
David R. Schoneker is currently an independent consultant and the President and Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries.
With over 42 years of experience working in these areas, he has developed strong networks with regulatory agencies and pharmacopeias around the world.
Sandra Klein is currently professor of biopharmaceutics and pharmaceutical technology. Prof. Klein is a board member of APV, an EuPFI associate and a member of AAPS, CRS, DPhG. Moreover, she is a member of the editorial board of several scientific journals.
Her current research is focused on developing predictive dissolution methods and dosage forms for special patient groups, particularly the paediatric and geriatric population.
Alvaro Goyanes is the Development Director and lead project researcher at FabRx. Moreover, he is lecturer at USC and UCL and a highly cited researcher by Clarivate Web of Science for the 2nd year in a row!
Alvaro holds a PhD in pharmaceutical technology and was one of the first researchers assessing opportunities of 3D printing using Fused Deposition Modeling (FDM) to manufacture oral dosage forms and medical devices.
Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London, Founder and Academic Lead of King’s College London Fight the Fakes. She leads her research group “The Raimi-Abraham Group”.
Her research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria.
Hans Platteeuw started in 2005 Avivia BV, an independent company specialized in pharmaceutical product development with a specific expertise in the development and intellectual property protection of specialty generics products and in guiding the initial finished product development from phase I all the way up to phase III and commercial production.
His specialty is translating lead compounds into pharmaceutical products that can be made cost effectively and put on a shelf in a pharmacy.
Chris Moreton is Vice President of FinnBrit Consulting and currently a member of the Excipient Monographs 2 Expert committee of the United States’ Pharmacopeia and also on the Board of the IPEC Foundation.
He has more than 30 years experience in the development of new drug candidates and generic drugs, in many therapeutic areas, using different dosage forms and routes of administration. But also in QA/QC and Technical Support in excipients and drug delivery.
Raphael Janousek works as a project manager at BIOGRUND GmbH. In his role as a project manager he is part of the global sales team and responsible for the DACH and Scandinavian market.
He holds a master’s degree in in Bio- and Pharmaceutical Analysis and a Dr. in Chemistry. With his strong scientific background he consults pharmaceutical and nutraceutical companies in customized formulation projects in Europe.
Ajaz Hussain is the President of The National Institute for Pharmaecuetical Technology & Education. His background includes decades of experience in industry, US FDA, and in academic research and teaching to include a number of high-level corporate leadership positions.
His career at US FDA spanned 10 years, where he served as the Deputy Director of the Office of Pharmaceutical Science (OPS) in the Center for Drug Evaluation and Research (CDER) and a “peer reviewed” Senior Biomedical Research position in the US Government Service.
Allison Labriola is a Senior Technical Sales Representative for JRS, specializing in Vivacoat. She supports film coatings from a sales and technical perspective throughout North America.
Allison has an extensive background in pharmaceutical coating and tablet formulation thanks to over 15 years of experience working in sales, technical, and manufacturing roles.
Dario Dornbierer studied pharmaceutical sciences at the ETH Zurich and holds a PhD in the field of sleep pharmacology. During his current bio-entrepreneurial PostDoc position at the University Hospital of Psychiatry in Zurich, he investigates the clinical potential of illicit drugs for the treatment of psychiatric disorders, such as GHB and Ayahuasca.
Moreover, he is continuously driving the research on how to optimize psychiatric drug therapies applying cutting-edge pharmaceutical technologies. Dario acts as Co-founder and CSO of Galventa.
Sascha Fritsche, CFA, has an MA in banking and finance from the University of St. Gallen (HSG). During several years he gathered insights into strategy consulting and banking while working for Helbling Management Consulting, Credit Suisse and Nomura.
In the past eight years, he acted as the CFO in an ETH-spin-off, which he accompanied on the journey from very few to over 200 employees. Sascha acts as Co-founder and CEO of Galventa.
Tomas Skrinskas has been at the leading edge of transformative health care technologies including computer assisted surgery, surgical robotics and genetic nanomedicines for over 15 years,
His career began with research and engineering which provided a strong foundation for the business development and operations roles that followed. Tomas founded Ascension Sciences, a R&D laboratory focused on nanoparticle development for cannabinoid products and therapeutics, in January 2019.
With nearly 30 years of experience in the Pharmaceutical and Nutritional industries, Larry currently is the Pharmaceutical / Nutraceutical Sales Manager at BENEO, Inc. in North America.
Larry started his career in the laboratory specializing in the development of aqueous and enteric film coating systems along with direct compression calcium and oyster shell products for solid dosage (tablet) applications at CHR Hansen formerly Crompton & Knowles ITC.
In his near 30 year career; Larry has worked not only for manufacturers of high quality excipients i.e.: Sensient Pharmaceuticals formerly Warner Jenkinson and JM Huber Corporation, he also worked for over 6 years at IMCD US LLC formerly Mutchler, Inc. whom distributed a large portfolio of excipients from manufacturers around the world.
Cross-functional team lead covering aspects of novel product and process development, regulatory strategy, intellectual property, and market assessment.
Member of the innovation teams responsible for development and regulatory entrée of 3D printed products in multiple medical fields. Over twenty years of experience applying 3D printing technology to pharmaceuticals and medical devices.
Familiar with startup to commercial stage corporate environment, ranging from a few people to over 100. Significant interaction with legal counsel across specialties, including FDA law, patent & trademark law, and contract law.
Pavel Abdulkin is the Chief Commercial Officer at Microcaps AG. He has over 10 years experience in development of nano- and microencapsulation techniques to enable controlled release and targeted delivery applications across pharmaceutical and nutraceutical industries.
At Microcaps Pavel is responsible for development and implementation of the commercial strategy as well as customer outreach and strategic partnerships.
Participants will have the chance to fix an appointment at your booth already before the event
During the event the exhibitors and sponsors are named and introduced prominently
You have the possibility to brand your booth and offer your information material
Our event schedule provides dedicated slots for visiting the exhibition.
Main Topics
3D Printing
Continuous Manufacturing
Drug Delivery